title: [TNF alfa modulators in the treatment of rheumatoid arthritis].
abstract: Current slow-acting anti-rheumatic drugs available at now for rheumatoid arthritis fail in majority of cases and have an inconstant chondro-protective effect. Improvements in our knowledge of its pathogenesis and advances in molecular biology have made possible to develop selective immunotherapy approaches. Tumor necrosis factor alfa (TNF alfa) is an important inflammatory mediator that play a crucial role in rheumatoid arthritis. This studies summarizes clinical essays that evaluate beneficial effects and tolerance of anti TNF alfa antibodies. This study showed the clinical, biological and radiological efficacy of these therapeutic agents. But some doubts persist concerning their long term side effects particularly infections, neoplasm or auto immune ones. High price of this treatment should evaluate report cost benefice to appreciate the better utilisation of these drugs.
authors.affiliation: Service de médecine interne, Hôpital Habib Thameur, Tunis, Tunisie.
authors.forename: Samir
authors.initials: S
authors.lastname: Kochbati
authors.forename: Fatma
authors.initials: F
authors.lastname: Boussema
authors.forename: Mohamed
authors.initials: M
authors.lastname: Ben Miled
authors.forename: Sonia
authors.initials: S
authors.lastname: Ktari
authors.forename: Lilia
authors.initials: L
authors.lastname: Daoud
authors.forename: Samir
authors.initials: S
authors.lastname: Ben Rhouma
authors.forename: Golsom
authors.initials: G
authors.lastname: Ben Amor
authors.forename: Ouahida
authors.initials: O
authors.lastname: Chérif
authors.forename: Lilia
authors.initials: L
authors.lastname: Rokbani
mesh_terms: D000906:Antibodies / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology*
chemical_list: D000906:Antibodies; D014409:Tumor Necrosis Factor-alpha